BACKGROUND The newer generation, nonsteroidal aromatase inhibitors (AIs) anastrozole
and letrozole have shown superior efficacy compared with tamoxifen as first‐line treatments …

Adverse drug–drug interactions are a major cause of morbidity and mortality. Cancer
patients are at particularly high risk of such interactions because they commonly receive …

Breast cancer is treated with a multidisciplinary approach involving surgical oncology,
radiation oncology, and medical oncology. The NCCN Clinical Practice Guidelines in …

BACKGROUND: In the adjuvant setting, tamoxifen is the established treatment for
postmenopausal women with hormone-sensitive breast cancer. However, it is associated …

Breast cancer is the most common malignancy in women in the United States and is second
only to lung cancer as a cause of cancer death. The overall management of breast cancer …

These NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast
Cancer are the work of the members of the NCCN Breast Cancer Panel. Categories of …

Until recently, the study of nuclear receptor (NR) function in breast cancer biology has been
largely limited to estrogen and progesterone receptors. The development of reliable gene …

Objective: Hormones have been implicated as modulators of cognitive functioning. For
instance, results of our previous work in women with breast cancer showed that cognitive …

Palbociclib, ribociclib and abemaciclib were recently approved as chemotherapeutic agents
and are currently in the post-marketing surveillance phase. They are used in combination …

Aromatase inhibitors (AIs) have a central role in the treatment of breast cancer; however,
resistance is a major obstacle to optimal management. Evidence from endocrine, molecular …